Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile

What Was Tested

This randomized controlled trial looks at IGF-1 LR3.

Who Took Part

The study group was 3 adults.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Participants were recruited from the communities of Winston Salem, NC, and Greensboro, NC.

Subjects > or = 55 years old with high cardiovascular disease risk profile.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

The adults were allocated by chance, so the IGF-1 LR3 group and the comparison group should start out alike.

Blinding on both sides kept the adults and researchers unaware of who received IGF-1 LR3.

A placebo (an inactive look-alike) gave the IGF-1 LR3 group a baseline to be compared against.

Each person switched between IGF-1 LR3 and the comparison at some point, usually with a gap in between.

Data are from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study, a double-blind, crossover, randomized, placebo-controlled trial.

Serum concentrations of total IGF-1 and IGFBP-3 were measured in 100 participants of the TRAIN study at baseline, 6-month and 12-month follow-up visits.

Differences in total IGF-1 and IGFBP-3 concentrations were assessed using two-sided paired ttests.

What Was Measured

Topics PubMed links to this paper include Angiotensin-Converting Enzyme Inhibitors, Biomarkers, Cardiovascular Diseases, Fosinopril, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I and Risk Factors.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of IGF-1 LR3 in 3 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (The journal of nutrition, health & aging), a journal based in France.

More context: the IGF-1 LR3 compound page, all human trials.